EV Biologics, Inc.

Total Valuation

EV Biologics, Inc. carries a market capitalization of 2,890.00, placing it among publicly traded companies globally. Its enterprise value stands at 8.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

EV Biologics, Inc. currently has 2.41M shares outstanding.

Valuation Ratios

EV Biologics, Inc. trades at a trailing price-to-earnings ratio of 0.67. The price-to-sales ratio is 0.02, and the price-to-book ratio stands at -0.04.

Enterprise Valuation

On an enterprise value basis, EV Biologics, Inc. trades at an EV/EBITDA multiple of 2.92 and an EV/FCF ratio of 0.19. The EV/Sales ratio of 0.14 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 4.07 provides insight into valuation relative to core operating earnings.

Financial Position

EV Biologics, Inc. maintains a current ratio of 0.33, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 155.08, indicating elevated leverage, while an interest coverage ratio of -0.42 demonstrates limited ability to service its debt obligations.

Financial Efficiency

EV Biologics, Inc. posts a return on equity of 44.38 and a return on invested capital of 15.52.

Taxes

Over the trailing twelve months, EV Biologics, Inc. has paid 4.78M in income taxes, reflecting an effective tax rate of 24.16.

Stock Price Statistics

EV Biologics, Inc.'s stock has declined approximately -99.50617% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.06.

Income Statement

Over the trailing twelve months, EV Biologics, Inc. generated 62.15M in revenue and converted that into -114.90M in net income, yielding earnings per share of -65.32. EBITDA reached -743,047.00, while operating income came in at -2.55M.

Balance Sheet

EV Biologics, Inc. holds 2.48M in cash and equivalents against 9.35M in total debt, resulting in a net debt position of 2.95M. Total book value stands at -37.04M, with working capital of -18.63M providing operational flexibility.

Cash Flow

EV Biologics, Inc. produced 5.01M in operating cash flow over the past twelve months. After subtracting -37.99M in capital expenditures, free cash flow totaled -32.98M - equivalent to -18.75 per share.

Margins

EV Biologics, Inc. operates with a gross margin of 38.03, reflecting its pricing power and cost economics. The operating margin of -4.10 and net profit margin of -184.87 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

EV Biologics, Inc.'s most recent stock split took place on November 9, 2017 with a 5:1 split ratio.

Scores

EV Biologics, Inc. posts an Altman Z-Score of -0.61, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.